Ipsen, bioMérieux ink personalized med partnership; Pearl Therapeutics names CEO;

@FierceBiotech: Pfizer's crizotinib eliminates signs of advanced lymphoma. Report | Follow @FierceBiotech

@JohnCFierce: Coviden, Valeant vet Chuck Bramlage named CEO at Pearl Therapeutics. News | Follow @JohnCFierce 

> Ipsen and bioMérieux have entered into a partnership on theranostics, with a focus on hormone-dependent cancers. The two companies will develop a personalized approach to medicine based on Ipsen's portfolio of compounds and bioMérieux's diagnostic tests. Release

> Zalicus published its preclinical results for Z212, a neuropathic pain therapy, in the journal PAIN. According to the results, Z212 reduces reverse pain hypersensitivity and neuron exciteablity. Zalicus release

> In a six to two decision, the Supreme Court has ruled that families can't sue drugmakers if their children suffered adverse effects from a vaccine. Story

> Pearl Therapeutics has named Chuck Bramlage President and CEO. Release

> Carlos Riva, CEO and President of Verenium is retiring while Executive Vice President James Levine steps up as the new CEO and President.  Verenium release

And Finally... Turns out a tree most farmers find a nuisance could help in the fight against MRSA. Researchers at the University of Missouri found an antibiotic in the Eastern Red Cedar that can combat MRSA infections. Release